Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug could simplify treatment for rare EGPA disease

NCT ID NCT04157348

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a newer drug, benralizumab, works as well as the current standard, mepolizumab, for people with a rare disease called EGPA that inflames blood vessels. About 140 adults with active EGPA will receive either drug for a year, along with their usual steroids. The goal is to see if benralizumab can help more patients achieve remission with fewer steroid side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Benralizumab (a biologic drug given as an injection)

What this could lead to

If benralizumab works as well or better than mepolizumab, it could offer a new treatment option for EGPA, potentially with fewer injections.

What could go wrong

This is a Phase 3 trial, but results are not yet final. Benralizumab may not prove superior or may have unexpected side effects. The study is also relatively small (140 participants).

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EOSINOPHILIC GRANULOMATOUS VASCULITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

eosinophilic granulomatosis with polyangiitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EOSINOPHILIC GRANULOMATOUS VASCULITIS

Contacts and locations

Locations

  • Research Site

    Denver, Colorado, 80206, United States

  • Research Site

    Ann Arbor, Michigan, 48109, United States

  • Research Site

    Rochester, Minnesota, 55905-0001, United States

  • Research Site

    Albuquerque, New Mexico, 87106, United States

  • Research Site

    Great Neck, New York, 11021, United States

  • Research Site

    New York, New York, 10021, United States

  • Research Site

    Philadelphia, Pennsylvania, 19104, United States

  • Research Site

    Denison, Texas, 75020, United States

  • Research Site

    Seattle, Washington, 98115, United States

  • Research Site

    Brussels, 1070, Belgium

  • Research Site

    Brussels, 1090, Belgium

  • Research Site

    Calgary, Alberta, T2N 4Z6, Canada

  • Research Site

    Hamilton, Ontario, L8N 4A6, Canada

  • Research Site

    Toronto, Ontario, M5G 1E2, Canada

  • Research Site

    Toronto, Ontario, M5T 3A9, Canada

  • Research Site

    Dijon, 21079, France

  • Research Site

    Marseille, 13915, France

  • Research Site

    Montpellier, 34090, France

  • Research Site

    Nantes, 44093, France

  • Research Site

    Paris, 75014, France

  • Research Site

    Paris, 75877, France

  • Research Site

    Suresnes, 92151, France

  • Research Site

    Toulouse, 31059, France

  • Research Site

    Bamberg, 96049, Germany

  • Research Site

    Freiburg im Breisgau, 79106, Germany

  • Research Site

    Hamburg, 20251, Germany

  • Research Site

    Kirchheim, 73230, Germany

  • Research Site

    Lübeck, 23538, Germany

  • Research Site

    Ashkelon, 7830604, Israel

  • Research Site

    Beersheba, 84101, Israel

  • Research Site

    Jerusalem, 91120, Israel

  • Research Site

    Ramat Gan, 52621, Israel

  • Research Site

    Rehovot, 7661041, Israel

  • Research Site

    Tel Aviv, 6423906, Israel

  • Research Site

    Cuneo, 12100, Italy

  • Research Site

    Florence, 50141, Italy

  • Research Site

    Milan, 20132, Italy

  • Research Site

    Milan, 20162, Italy

  • Research Site

    Naples, 80131, Italy

  • Research Site

    Roma, 00168, Italy

  • Research Site

    Torino, 10128, Italy

  • Research Site

    Chiba, 260-0877, Japan

  • Research Site

    Kita-gun, 761-0793, Japan

  • Research Site

    Sagamihara-shi, 228-0815, Japan

  • Research Site

    Sendai, 980-8574, Japan

  • Research Site

    Shinjuku-ku, 162-8666, Japan

  • Research Site

    Cambridge, CB2 0QQ, United Kingdom

  • Research Site

    Leicester, LE3 9QP, United Kingdom

  • Research Site

    London, SE19RT, United Kingdom

  • Research Site

    Portsmouth, PO6 3LY, United Kingdom